Ensho Therapeutics Revenue and Competitors
Employee Data
- Ensho Therapeutics has 8 Employees.
Ensho Therapeutics's People
| Name | Title | Email/Phone |
|---|
Ensho Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 48 | -9% | N/A | N/A |
#10 | $16.1M | 88 | 4% | N/A | N/A |
What Is Ensho Therapeutics?
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.
keywords:N/A
N/A
Total Funding
8
Number of Employees
N/A
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.6M | 8 | N/A | N/A |
#2 | $0.6M | 8 | N/A | N/A |
#3 | $0.6M | 8 | N/A | N/A |
#4 | $0.6M | 8 | N/A | N/A |
#5 | $0.6M | 8 | N/A | N/A |